Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Abstract Text:

H Schulz,J Bohlius,N Skoetz,S Trelle,T Kober,M Reiser,M Dreyling,M Herold,G Schwarzer,M Hallek,A Engert,H Schulz,J Bohlius,N Skoetz,S Trelle,T Kober,M Reiser,M Dreyling,M Herold,G Schwarzer,M Hallek,A Engert,

BACKGROUND: Rituximab has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma. However, the impact of R on overall survival (OS) when given in combination with chemotherapy (R-chemo) has remained unclear so far. OBJECTIVES: We thus performed a comprehensive systematic review in this group of patients to compare R-chemo with chemotherapy alone with respect to OS. Other endpoints were overall response rate (ORR), toxicity and disease control as assessed by measures such as time to treatment failure (TTF), event free-survival (EFS), progression free-survival (PFS) and time to progression (TTP). SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE and conference proceeding from 1990 to 2005. SELECTION CRITERIA: Only randomised controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL) were included. DATA COLLECTION AND ANALYSIS: Two review authors extracted data and assessed the study quality. Number needed to treat (NNT) were calculated to facilitate interpretation. MAIN RESULTS: Seven randomised controlled trials involving 1943 patients with follicular lymphoma, mantle cell lymphoma, or other indolent lymphomas were included in the meta-analysis. Five studies were published as full-text articles, and two were in abstract form. Patients treated with R-chemo had better overall survival (hazard ratio [HR] for mortality 0.65; 95% confidence interval (CI) 0.54 to 0.78), overall response (relative risk of tumour response 1.21; 95% CI 1.16 to 1.27), and disease control (HR of disease event 0.62; 95% CI 0.55 to 0.71) than patients treated with chemotherapy alone. R-chemo improved overall survival in patients with follicular lymphoma (HR for mortality 0.63; 95% CI 0.51 to 0.79) and in patients with mantle cell lymphoma (HR for mortality 0.60; 95% CI 0.37 to 0.98). However, in the latter case, there was heterogeneity among the trials (P 0.07), making the survival benefit less reliable. AUTHORS' CONCLUSIONS: The systematic review demonstrated improved OS for patients with indolent lymphoma, particularly in the subgroups of follicular and in mantle cell lymphoma when treated with R-chemo compared to chemotherapy alone.

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Publishing Authors By Initials

H Schulz,J Bohlius,N Skoetz,S Trelle,T Kober,M Reiser,M Dreyling,M Herold,G Schwarzer,M Hallek,A Engert,H Schulz,J Bohlius,N Skoetz,S Trelle,T Kober,M Reiser,M Dreyling,M Herold,G Schwarzer,M Hallek,A Engert,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Journal Published:

PUBLICATION TYPE: Review

Journal: Cochrane database of systematic reviews (Online)

VOLUME:

Page Numbers: CD003805

Journal Abbreviation:

ISSN: 1469-493X

DAY: 17

MONTH: 10

YEAR: 2007

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Information

Number of References: 67

LANGUAGE: eng

NlmUniqueID: 100909747

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

AFFILIATION: Univerisity Hospital Cologne, Cochrane Haematological Malignancies Group - Department of Internal Medicine 1, Kerpener Str 62, Köln (Cologne), Germany, D 50924. Holger.Schulz@uni-koeln.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cochrane Database Syst Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Related Publications

• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
• Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
• Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
• Control of visually guided behavior by distinct populations of spinal projection neurons.
• Current treatment strategies of the German Hodgkin Study Group (GHSG).
• Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
• Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
• Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons.
• Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
• Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study.
• Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
• Hodgkin's disease. Future treatment strategies: fact or fiction?
• Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells.
• Immunotherapy of Hodgkin's lymphoma.
• K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
• Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
• Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
• [Antibiotic therapy of endocarditis lenta.]
• [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]
• [Thoracic surgery emergencies in early childhood]